CDH1 and invasive breast carcinoma: For example, E-Cadherin positivity has been described in 25 to 100% of invasive breast carcinoma of no special type [20–22], 32 to 100% of oral squamous cell carcinomas [23–25], 31 to 100% of intestinal gastric carcinomas [26–28], 26 to 100% of colorectal adenocarcinomas [29–31], and 5 to 54% of clear cell renal cell carcinomas [17, 32, 33].